ARTICLES BY LOUIS

• CDMOs Should Take On More Project Ownership

  "I want to hire CDMOs that take shared accountability and more ownership of the projects, products, and of the relationship." says a biopharma executive. You should, too. Here's how.

• Wanted: Multi-Experienced Employees For Outsourcing

  Jana Spes of Ironwood Pharmaceuticals provides uniquely qualified analysis and guidance on working with CDMOs. Don’t be surprised if you come away thinking for your next hire, specialization is out, and the Spes model is in.

• 2 Years For Vaccine Tech Transfers? COVID-19 Won’t Wait

  A McKinsey & Company report, “Why tech transfer may be critical to beating COVID-19,” indicates the typical time to tech transfer a new vaccine is 27-29 months. Over 2 years for a tech transfer? Experts say yes. But not for COVID-19.

• 2 CDMOs Better Than All-In-One: The “Best-In-Breed” Trend

  We’ve uncovered a global trend in drug development and manufacturing outsourcing. I spoke to senior executives at four service providers to learn the trend is part antidote – and potentially a better option – to the “one-stop-shop” composite.

• Is PhRMA’s White House Rebuttal Acceptable?

  While the biopharmaceutical industry can only be commended for the work underway to bring the world vaccines and therapies to halt the spread and severity of COVID-19, it would be ironic if PhRMA uses the pandemic as leverage to maintain the drug supply-chain status quo.

• Shedding Light On Outsourcing Shadows

  A new report sheds some light on biotech and pharma contract service agreements (CSAs) with CDMOs. Despite remaining shadows, it reveals less multiservice relationships and more large-molecule announcements than we might have expected.

• A Word From Germany On U.S. Manufacturing Productivity

  Of 367 production plants BASF operates worldwide, six are Verbund sites. Those six produce more than 50% of all BASF volumes. A CEO of a U.S.-based CDMO thinks Verbund is the kind of thinking needed at drug development and manufacturing facilities in this country.

• U.S. The “Destination” For Outsourcing: Will CDMO Capacity Hold Up?

  According to a new industry report on global bioprocessing, U.S.-based CDMOs are in a strong position. Is it so strong that capacity becomes an issue for readers relying on these service providers for new drug programs?

• E-A-T Your CDMO: What Google Teaches Biotech About Partner Selection

  CDMO search and evaluation are at the core of drug development and manufacturing outsourcing. Google, the company that built an empire on returning high-quality search results, makes a case for E-A-Ting your CDMO partners.

• Novartis, Anthos, Lonza, And Investors In the Middle Of It All

  Jonathan Freeman of Anthos Therapeutics says it’s “economic Darwinism” come visit the pharma world. Karen Fallen of Lonza admits it's “potentially highly complex.” Both believe today it's a reproducible “value-creation model.”